Daniel Lyons, PhD, CFA

Portfolio Manager | Research Analyst
Daniel Lyons, Ph.D., CFA | Janus Henderson Investors

Daniel Lyons is a Portfolio Manager and Research Analyst at Janus Henderson Investors responsible for co-managing the Biotechnology strategy since 2018. Daniel started consulting for Janus in 1997 and joined the Health Care Sector Research Team full time in 2000. As a research analyst, he focuses on the biotechnology and life science tools sectors.

Daniel received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a PhD from Stanford University’s programme in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 20 years of financial industry experience.

Products Managed

Articles Written

Podcast: Understanding the science and investment implications of COVID-19 (part 7)

Podcast: Understanding the science and investment implications of COVID-19 (part 7)

In our ongoing series on COVID-19, Portfolio Manager and Research Analyst Dan Lyons and Director of Research Matt Peron discuss the current state of the pandemic and what investors should consider as the economy tries to return to “normal.”

Podcast: Understanding the science and investment implications of COVID-19 (part 4)

Podcast: Understanding the science and investment implications of COVID-19 (part 4)

In this fourth installment of a series on the scientific and investment implications of COVID-19, Portfolio Manager and Research Analyst Dan Lyons explains the latest drug developments, as well as whether the US can meet its aggressive testing goals to reopen the economy.